>>Description of the research protocol "CQAWO39 A2307"

A 52-week, multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma.
Phase III study| Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Immuno-allergologie
Brugmann identifier : CQAWO39 A2307
EudraCT identifier : 2015-002553-35


Involved department : Immuno-allergology
Principal investigator : Michel
Sponsor : novartis
Contact : Clinical Research Unit

>This protocol was approved by the St Pierre ethics committee.